For many labs, toxicology has long been a top target for payer audits. Reimbursement cuts and stricter “medical necessity” interpretations are raising denials, claw-backs, and scrutiny, especially around frequency of testing and documentation quality. At the same time, the opioid crisis demands careful clinical oversight to prevent patient harm.
During a Sept. 29, 2025, webinar, Lighthouse Lab Services hosted compliance and legal experts to discuss the considerations facing opioid providers as they seek to ensure patient safety while also maintaining consistent reimbursement for their services.
- Speakers: Ellen Beausang (CRO & President, Lighthouse Lab Services), Dr. Michael Sprintz (CEO & Founder, Cellarian), and Jane Pine Wood (Counsel, McDonald Hopkins)
As noted by Dr. Sprintz, the key to maintaining your ability to receive compliant reimbursement comes down to maintaining proper documentation, including risk assessments, where appropriate.
“Better documentation on the front end equals higher likelihood of reimbursement and revenue retention on the back end,” Sprintz says.
Key Takeaways for Opioid Providers
To set the foundation, here are the core principles every lab should be aware of when managing opioid testing compliance:
- Documentation drives outcomes. If it’s not documented, it “didn’t happen”, clinically or for reimbursement.
- Risk isn’t just addiction. Broaden opioid risk to include all opioid-related harms (e.g., respiratory depression, falls, CNS depressant co-prescribing).
- Local Coverage Determinations (LCDs) tie testing frequency to risk. Labs need clear rationale for the assigned risk level to support frequency.
- Screening tools are one data point. Validated tools (e.g., ORT, SOAPP) are not the sole basis for risk; most payers have removed requirements that they be used alone.
- Independent vs. POL realities. Reference labs must educate providers and collect usable documentation; Physician Office Labs (POLs) should embed risk rationale directly in the chart.
- Panel breadth vs. frequency. Don’t conflate the number of drug classes (panel size) with how often testing occurs. Each raises different compliance questions.
- Download the full Comprehensive Opioid Risk Assessment Worksheet.
The Four Documentation Elements Payers Expect
Many labs focus solely on whether they have an order for testing, but that’s only one piece of the puzzle. When labs are audited, payers want to see a clear story: Why was the test ordered, was it performed, and how was it used?
From a legal and clinical perspective, patient harm risk must remain central. Malpractice exposure rises when testing is inadequate or test results are not reviewed and incorporated into care plans. That’s why complete documentation matters even when you anticipate limited coverage.
“We’re not just worried about getting paid: what are the consequences of a failure to test or to adequately test?”, Sprintz notes.
According to Pine Wood, auditors consistently look for:
- Reason for testing drawn from the medical record (clinical context justifying the test)
- Signed order by the provider
- Test result showing the service was performed
- Evidence the provider reviewed/used the result in diagnosis or treatment
“From a payer standpoint, if it’s not documented, it was never done,” she says.
Rethinking “Risk”: Beyond Addiction Scores
While validated screening tools are valuable, providers must move beyond relying on a numerical score. Self-reported tools are often inaccurate, and clinical risk extends far beyond addiction potential.
Sprintz also emphasizes providers should widen their lens and look beyond simple risk assessment tools or scores:
- Validated screening tools are useful, but are typically self-reported and prone to under-reporting.
- Risk should include opioid-related harms (e.g., respiratory depression, overdose, falls), not just opioid use disorder (OUD).
Clinical example: An 83-year-old patient on hydrocodone and gabapentin with COPD may score “low” on an OUD tool yet be high clinical risk for respiratory depression and falls.
“These tools are not addiction-diagnosis genies,” Sprintz cautions. “Overreliance on a single score leads to the wrong risk conclusions and denials.”
LCDs & Frequency of Testing: Why Labs Are Failing Audits
LCDs now explicitly tie testing frequency to the assigned risk level (low, moderate, or high). Monthly testing without supporting documentation is no longer defensible. That’s why labs are seeing failures during TPE and post-payment audits.
MAC LCDs increasingly tie testing frequency to risk level (e.g., low, moderate, high). If the only risk evidence is a low self-reported score, monthly testing can become indefensible, even when clinically appropriate.
Common audit pain points
- No risk documentation beyond a screening score
- Frequency above LCD limits without rationale
- Inconsistent use documentation (results not shown as applied to care)
Ellen Beausang, President, CRO, LLS
Labs should look to align with the most conservative applicable payer/MAC policy in your markets to reduce rework and denials, Beausang advises.
To bridge the gap between clinical reality and reimbursement requirements, the panel highlighted a one-page provider-completed worksheet (not a validated score) that:
- Consolidates biopsychosocial and medical risk factors (e.g., CNS depressants, sleep apnea, COPD, cognitive issues, psychiatric comorbidity, prior inconsistent confirms)
- Captures a clinician’s rationale for low/moderate/high risk
- Can optionally include validated screening tool results as a supporting data point
“Risk assessment is a clinical decision, not a score,” says Sprintz. “What payers want is documented rationale.”
How to implement these tools
- POLs: Use it at least annually (or when clinical status changes) and store in the chart.
- Reference labs: Offer it as provider education, and encourage attaching it (or its key elements) to requisitions or EHR workflows.
Frequency: Ideally each visit; practically, at least once per year or with any material clinical change.
Operational Tactics for Labs
For Independent/Reference Labs
- Educate providers on required elements; share the worksheet and a one-pager on LCD frequency rules.
- Add requisition checkboxes aligned to conservative payer policy (without forcing entries) to capture risk factors and clinical indications.
- Build a cover-sheet narrative when responding to audits: connect the dots across order, rationale, results, and evidence of use.
“Don’t assume an auditor will connect the dots, make it easy with a brief narrative,” advises Sprintz.
For Physician-Owned Labs (POLs)
- Embed risk rationale and “evidence of result use” directly in progress notes or standardized intake workflows.
- When medically necessary testing may not be covered, consider appropriate modifiers (e.g., GY for Medicare non-covered services) and obtain ABNs where applicable (consult counsel/payer policy).
Panel Breadth vs. Frequency: Two Different Issues
Labs often confuse documentation for panel size with documentation for testing frequency. Payers can challenge both, but for different reasons. Payers may cap or presume lack of necessity for broad confirmation panels (e.g., >14 drug classes). Options include:
- Document clinical justification (e.g., new addiction patient with unknown exposures, street drug variability) for broader panels.
- Recognize the industry practice of running larger internal panels while billing for the covered subset, but do not market “bigger testing for the price of smaller.”
- Revisit class mapping: many analytes can roll into fewer drug classes, affecting coverage logic.
Policies evolve and rarely become more permissive. Standardize to the most conservative active policy to minimize changes and improve appeal success.
“Payers tend to migrate toward the most conservative policy in a jurisdiction, so plan accordingly,” Beausang, says.
How Lighthouse Lab Services Can Help
Lighthouse supports labs with RCM strategy, compliance education, documentation best practices, and provider training, including resources like the Comprehensive Opioid Risk Assessment Worksheet and requisition design guidance.
If your lab is facing rising denials, TPE audits, or questions about frequency and panel construction, our team can help you stabilize reimbursement while protecting patient care.
